Abstract

For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCancer growth and metastasis
Volume9
DOIs
Publication statusPublished - 2016

Fingerprint

Blood Component Transfusion
Growth
Neoplasms
Precision Medicine
Blood Cell Count
Immunologic Factors
Blood Platelets
Biomarkers
Hemorrhage
Therapeutics

Keywords

  • Journal Article
  • Review

Cite this

Goubran, H. A., Elemary, M., Radosevich, M., Seghatchian, J., El-Ekiaby, M., & Burnouf, T. (2016). Impact of Transfusion on Cancer Growth and Outcome. Cancer growth and metastasis, 9, 1-8. https://doi.org/10.4137/CGM.S32797

Impact of Transfusion on Cancer Growth and Outcome. / Goubran, Hadi Alphonse; Elemary, Mohamed; Radosevich, Miryana; Seghatchian, Jerard; El-Ekiaby, Magdy; Burnouf, Thierry.

In: Cancer growth and metastasis, Vol. 9, 2016, p. 1-8.

Research output: Contribution to journalReview article

Goubran, HA, Elemary, M, Radosevich, M, Seghatchian, J, El-Ekiaby, M & Burnouf, T 2016, 'Impact of Transfusion on Cancer Growth and Outcome', Cancer growth and metastasis, vol. 9, pp. 1-8. https://doi.org/10.4137/CGM.S32797
Goubran, Hadi Alphonse ; Elemary, Mohamed ; Radosevich, Miryana ; Seghatchian, Jerard ; El-Ekiaby, Magdy ; Burnouf, Thierry. / Impact of Transfusion on Cancer Growth and Outcome. In: Cancer growth and metastasis. 2016 ; Vol. 9. pp. 1-8.
@article{5d33636dd401485d86a03ddd7bd4850d,
title = "Impact of Transfusion on Cancer Growth and Outcome",
abstract = "For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.",
keywords = "Journal Article, Review",
author = "Goubran, {Hadi Alphonse} and Mohamed Elemary and Miryana Radosevich and Jerard Seghatchian and Magdy El-Ekiaby and Thierry Burnouf",
year = "2016",
doi = "10.4137/CGM.S32797",
language = "English",
volume = "9",
pages = "1--8",
journal = "Cancer growth and metastasis",
issn = "1179-0644",

}

TY - JOUR

T1 - Impact of Transfusion on Cancer Growth and Outcome

AU - Goubran, Hadi Alphonse

AU - Elemary, Mohamed

AU - Radosevich, Miryana

AU - Seghatchian, Jerard

AU - El-Ekiaby, Magdy

AU - Burnouf, Thierry

PY - 2016

Y1 - 2016

N2 - For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.

AB - For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.

KW - Journal Article

KW - Review

U2 - 10.4137/CGM.S32797

DO - 10.4137/CGM.S32797

M3 - Review article

C2 - 27006592

VL - 9

SP - 1

EP - 8

JO - Cancer growth and metastasis

JF - Cancer growth and metastasis

SN - 1179-0644

ER -